ʻO Tirzepatide Lyophilized High Purity 99% Peptide Powder 60mg i kēlā me kēia vial no ka maʻi maʻi a me ka poho kaumaha

Tirzepatide Lyophilized Pahu (60 mg)

ʻO Tirzepatide (LY3298176) ka mea mua ʻelua-acting agonist e kuhikuhi ana i ka GIP (glucose-dependent insulinotropic polypeptide) a me GLP-1 (glucagon-like peptide-1). Ua loaʻa iā ia ka ʻae ʻana o US FDA i Mei 2022 no ka mālama ʻana i ka maʻi maʻi type 2 (T2DM) ma ke ʻano he mea hoʻohui i ka meaʻai a me ka hoʻoikaika kino.
Hāʻawi ʻia kēia huahana ma ke ʻano he 60mg lyophilized (freeze-dried) sterile pauka i loko o nā hue, pono e hoʻohui hou ʻia me ka wai bacteriostatic ma mua o ka lawelawe ʻana. Hoʻohālikelike ʻia me ka GLP-1 receptor agonists e like me semaglutide a i ʻole dulaglutide, hōʻike ʻo tirzepatide i ka maikaʻi o ka hoʻomaikaʻi ʻana i ka hoʻoponopono glucose koko, hoʻonui i ka ʻike insulin, a me ke kākoʻo ʻana i ke kaumaha nui. Hāʻawi ʻia kēia mau pōmaikaʻi i kāna ʻano hana synergistic dual-receptor o ka hana.

Nā Pōmaikaʻi Nui
Hoʻoponopono Glycemic

• Hoʻoulu i ka huna ʻana o ka insulin ma ke ʻano pili i ka glucose
• Hoʻemi i ka huna ʻana o ka glucagon, hoʻohaʻahaʻa pono i nā pae glucose koko
• Hoʻohālike i nā hopena metabolic hui o GIP a me GLP-1

Hoʻoponopono kaumaha

• Hoʻonui i ka māʻona a hoʻemi i ka ʻai caloric
• Hōʻike i ka nui a me ka hoʻomau mau ʻana i ke kaumaha ma nā haʻawina lāʻau lapaʻau

Ola maʻi puʻuwai

• Hōʻike ka ʻikepili mua i ka hōʻemi ʻana i ka pilikia cardiovascular i nā maʻi me T2DM

Hoʻohana a me ka hoʻohana ʻana

• Pono e hana hou ʻia ʻo Tirzepatide lyophilized powder (60 mg) me ka wai bacteriostatic ma mua o ka hoʻohana ʻana. ʻO ka hoʻoponopono ʻana ma ke ʻano subcutaneous injection, maʻamau i hoʻokahi pule i ka lā hoʻokahi i kēlā me kēia pule.

ʻAno maʻi diabetes 2

• Ka hoʻomaka ʻana: 2.5 mg i hoʻokahi pule
• Titration: E hoʻonui i kēlā me kēia 4 pule e like me ka ʻae ʻia
• (→ 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg → 20 mg → 30 mg → 45 mg → a hiki i 60 mg)
• ʻO ka maʻamau maʻamau: 10-30 mg i kēlā me kēia pule
• Ka palena kiʻekiʻe: 60 mg i kēlā me kēia pule

Obesity / Kaumaha

• Ka hoʻomaka ʻana: 2.5 mg i hoʻokahi pule
• Titration: Hoʻonui ʻia ka nui o ka nui e like me ka ʻae ʻia
• (2.5 → 5 → 7.5 → 10 → 12.5 → 15 → 20 → 30 → 45 → 60 mg)
• Ka nui maʻamau: 30-60 mg i kēlā me kēia pule
• Ka palena kiʻekiʻe: 60 mg i kēlā me kēia pule

Hoʻohālikelike ʻia i ka Dosage

Nānā:E hōʻoia i kēlā me kēia maʻi mua e ʻae maikaʻi ʻia ma mua o ka piʻi ʻana.

ʻO nā hopena ʻino paha

• ʻO ka ʻōpū: Nausea, luaʻi, ka ʻōpū, a me ka ʻeha o ka ʻōpū (maʻamau i ka wā hoʻomaka)
• Hypoglycemia: He haʻahaʻa loa ka pilikia, akā ua hoʻonui ʻia ke hui pū ʻia me nā lāʻau antidiabetic ʻē aʻe
• Nā pane o ka pūnaewele injection: ʻulaʻula, ʻili, pehu, a i ʻole ʻeha ʻeha ma ka pūnaewele
• Pancreatitis: Kakaikahi akā hiki; nānā no ka ʻeha ʻōpū mau
• Nā hopena o ka Renal: Pono paha ka nānā ʻana i ka hana ʻana o ke kīpē i kekahi poʻe

Pharmacokinetics

• Half-Life: Ma kahi o 1 pule
• Dosing Frequency: Kākoʻo maʻalahi i ka hoʻokele hoʻokahi pule

Hōʻuluʻulu manaʻo
ʻO Tirzepatide 60 mg lyophilized pauka e hōʻike ana i ka holomua therapeutic o ka hanauna e hiki mai ana, e hui pū ana i ka mana glycemic ikaika me ka maikaʻi o ka pohō kaumaha a me ka pale cardiovascular.
Me ka papa kuhikuhi titration lohi (2.5 mg → a hiki i 60 mg), hiki iā ia ke hoʻonui i ka hoʻomanawanui a me ka maʻalahi no ka mālama pilikino. ʻO kāna hoʻokele hoʻokahi pule i hoʻomaikaʻi i ka pili ʻana, e lilo ia i koho hou a maikaʻi hoʻi no ka mālama ʻana i ka maʻi maʻi type 2 a me ka momona i nā hoʻonohonoho hoʻokolohua holomua a me ka noiʻi.